drugset / Trial / NCT01636206

Safety Study of Lifitegrast to Treat Dry Eye

NCT01636206

Phase 3 Completed 332 enrolled Shire
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the safety of lifitegrast ophthalmic solution compared to placebo in the treatment of dry eye as assessed by ocular and non-ocular adverse events when administered BID for approximately 1 year.

Timeline

Start
2012-10-16
Primary completion
2014-03-03
Completion
2014-03-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lifitegrast Unknown 5 % Other

Indications